Use of Homeopathy in Patients Suffering From Long COVID-19 (LONGCOVIHOM)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06002230 |
Recruitment Status :
Completed
First Posted : August 21, 2023
Last Update Posted : August 22, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Adjustment Reaction With Physical Symptoms | Drug: Homeopathic medicines |
All patients had been tested positive for SARS-CoV-2 before having developed Long-COVID-19 symptoms. Several testing methods were carried out in each patient to analyze a SARS-CoV-2 infection. For a confirmed infection, at least 3 out of these 5 tests had to be positive. Tests for the orthomyxoviruses influenza A and B, human metapneumovirus (hMPV) and paramyxoviruses were negative unless stated otherwise.
The homeopathic physician treated all Long-COVID-19 patients by individualized homeopathy. Repertorization of the symptoms of the current pandemic and a search in the current homeopathic literature on COVID-19 was performed using computer program. All available homeopathic medicinal products (HMPs) could be chosen by the treating physician.
Modified MONARCH criteria were assessed post hoc by all authors. Deviations were solved by discussion in person. Clinical outcome of case reports was evaluated using the "Modified Naranjo Criteria for Homeopathy-Causal Attribution Inventory". Eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.
Study Type : | Observational |
Actual Enrollment : | 15 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Use of Homeopathy in Patients Suffering From Long COVID-19 (LONGCOVIHOM): A Retrospective Case Series |
Actual Study Start Date : | January 5, 2021 |
Actual Primary Completion Date : | October 19, 2021 |
Actual Study Completion Date : | August 10, 2023 |
Group/Cohort | Intervention/treatment |
---|---|
Patients treated with individualized homeopathy
Patients suffering from symptoms of Long COVID-19 were treated with individualized homeopathy.
|
Drug: Homeopathic medicines
Globules were administered orally..
Other Name: Homeopathic medicinal products |
- Modified Naranjo criteria [ Time Frame: 3 days ]10 Naranjo criteria are evaluated, eight points is assumed as the limit for potential correlation between homeopathic therapy and amelioration of the symptoms or healing in chronic cases.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Long COVID-19 symptoms following recovery from SARS-CoV-2 infection
Exclusion Criteria:
Patients not signing informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06002230
Austria | |
Sigmund Freud Private University | |
Vienna, Austria, 1020 |
Study Director: | Michael Frass, MD | Institute for Homeopathic Research |
Responsible Party: | Michael Frass, Clinical professor, Medical University of Vienna |
ClinicalTrials.gov Identifier: | NCT06002230 |
Other Study ID Numbers: |
111 |
First Posted: | August 21, 2023 Key Record Dates |
Last Update Posted: | August 22, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Complementary therapy Homeopathy COVID-19 Long-COVID-19 SARS-CoV-2 |
COVID-19 Post-Acute COVID-19 Syndrome Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases Coronavirus Infections Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Post-Infectious Disorders Chronic Disease Disease Attributes Pathologic Processes |